Developer docs
API playgroundTry for free, no card

Search company profiles

Canopy Growth

Full company profile

uuid0000718

Namestring
Canopy Growth
Legal namestring
Canopy Growth Corporation
Company typeenum
Public
Founded yearint
2003
Descriptiontext

Canopy Growth Corporation is a Canadian publicly traded cannabis consumer products company (TSX: WEED, NASDAQ: CGC) headquartered in Smiths Falls, Ontario, with operations spanning medical cannabis cultivation, recreational cannabis branded products, medical vaporizer devices, and pharmaceutical manufacturing. Founded in 2003, the company operates a portfolio of more than 15 cannabis brands including Tweed (flagship consumer brand), 7Acres (premium flower), Doja (craft), Deep Space (high-potency beverages and gummies), Wana (edibles), Twd. and Deelish (value segments), and Spectrum Therapeutics (international medical). It also owns Storz & Bickel, a German manufacturer of medical-grade vaporizers including the Volcano Medic 2 with ISO 13485 certification, and Canopy Medical, a German pharmaceutical manufacturer for medical cannabis products. Distribution reaches Canada (provincial retailers plus company-owned Tweed and Tokyo Smoke stores), Germany (the largest European medical cannabis market), UK, Poland, Czech Republic, and Australia, with the company claiming product availability in over 50 countries.

The company generates revenue primarily through one-time product sales of dried cannabis flower, pre-rolls, vape cartridges, edibles, beverages, gummies, and softgels across Canadian recreational and medical markets plus international medical cannabis channels, supplemented by hardware sales of vaporizer devices and professional services revenue from Apollo Cannabis Clinics virtual consultations and Canada House clinics acquired through MTL Cannabis. Canopy operates over 10.5 million square feet of cultivation capacity including over 1 million square feet GMP-certified, and recently completed the acquisition of MTL Cannabis Corp. for approximately $125 million CAD in March 2026, which is expected to deliver $10 million in annualized synergies within 18 months. The company has undergone significant financial restructuring, moving from a net debt position of $172.6 million to a net cash position of $131.3 million through a January 2026 recapitalization that included a $150 million USD term loan and extension of all debt maturities to at least January 2031, with management targeting positive adjusted EBITDA by FY2027.

Constellation Brands holds approximately 38.6% of common shares as the largest shareholder following cumulative investments exceeding C$5 billion. FY2026 net revenue was $284.6 million (6% growth YoY), with notable momentum in Canadian medical cannabis (27% Q4 YoY growth) and international markets (68% Q4 YoY growth). The company is pursuing U.S. market entry through Canopy USA contingent on federal THC permissibility, leveraging its Acreage Holdings option arrangement, and faces a Management Cease Trade Order from the Ontario Securities Commission requiring restatement of FY2024 and FY2025 results due to non-cash warrant accounting issues.

Short descriptiontext

Canopy Growth is a Canadian publicly traded cannabis company that manufactures and sells medical and recreational cannabis products, medical vaporizers, and cannabis-infused consumer goods across Canada, Germany, and other international markets through a portfolio of 15+ brands.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
501–1,000
akta.pro rankint
HeadquartersSmiths Falls, Canada
HQ citystring
Smiths Falls
HQ countrystring
Canada
HQ regionstring
North America
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
cannabis products, medical cannabis, cannabis cultivation, vaporizer devices, cannabis brands
Industry4 codes
1Cannabis Dispensary + Delivery/Online Pickup (Omnichannel Retail)
CodeCRANAFAGPrimaryYes
2Cannabis Dispensary + Ancillary Retail (Accessories, CBD/Hemp, Merchandise)
CodeCRANAFAHPrimaryNo
3Dispensary-Owned Online Ordering & Delivery (Direct-to-Consumer)
CodeCRANAGAEPrimaryNo
4Cannabis Accessories & Smoke Shops (Pipes, Papers, Grinders)
CodeCRANAHAGPrimaryNo
NAICS code1 code
  • Tobacco Manufacturing3122
SIC code1 code
  • Medicinal Chemicals & Botanical Products2833
Product category
Cannabis Products
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model4 records
1Cannabis Product Sales
TypeOne Time License
Description

Revenue from selling dried cannabis flower, pre-rolls, vape cartridges, edibles, beverages, and gummies through Canadian recreational and medical markets, as well as international medical cannabis markets

gurufocus.com
2Medical Device Sales (Storz & Bickel)
TypeHardware Sales
Description

Revenue from manufacturing and selling vaporizer devices for medical and consumer use, including Volcano, Crafty, and Mighty product lines

canopygrowth.com
3Cultivation Services
TypeOne Time License
Description

Revenue from medical cannabis cultivation and processing, including premium flower production through MTL Cannabis facilities serving Canadian and international markets

mjbizdaily.com
4Medical Cannabis Clinics
TypeProfessional Services
Description

Revenue from Apollo Cannabis Clinics providing virtual medical cannabis consultations across Canada

businesswire.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Supply Chain, Operations, Marketing or Sales, Technology or R&D, Infrastructure
GTM typeB2C
B2C
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 3 records shown
1Apollo Cannabis Clinics
Description

Virtual medical cannabis clinic offering consultations across Canada

businesswire.com
+2 more records
Core offering1 text field

Canopy Growth is a diversified cannabis company that cultivates, manufactures, and sells cannabis products—including dried flower, pre-rolls, vape cartridges, edibles, beverages, and softgels—through a portfolio of 15+ brands across Canadian recreational, Canadian medical, and international medical cannabis markets. The company also produces medical-grade vaporizer devices through its Storz & Bickel subsidiary and operates virtual medical cannabis clinics through Apollo Cannabis Clinics and Canada House Clinics.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • 27% growth in Canadian medical cannabis net revenue in Q4 FY2026
+3 more records
Product overview1 text field

Canopy Growth is a diversified cannabis company operating a multi-brand portfolio across recreational and medical cannabis segments. The product portfolio spans multiple categories including dried flower, pre-rolls, vape cartridges, beverages, gummies, softgels, and medical devices. Core Canadian consumer brands include Tweed (flagship), 7Acres (premium flower), Doja (craft), Deep Space (beverages), Wana (gummies), Hiway (value), and Twd. (affordable simple products). Medical cannabis is served through Spectrum Therapeutics internationally and Apollo Cannabis Clinics in Canada. The company also owns Storz & Bickel, a leading vaporizer manufacturer producing medical-grade devices including Volcano Medic 2. The recent acquisition of MTL Cannabis added premium flower cultivation capabilities and medical clinic operations (Canada House). Products range from budget/value offerings (Deelish, Twd.) to premium/specialty tiers (Doja, 7Acres, Claybourne), with the Storz & Bickel subsidiary providing medical device technology across multiple regulated markets.

Product and service16 records
1Tweed
CategoryRecreational Cannabis
Description

Flagship cannabis brand offering dried flower, pre-rolls, and other cannabis products to recreational and medical consumers globally.

27Acres
CategoryRecreational Cannabis
Description

Premium cannabis brand producing high-end dried flower and pre-roll products for cannabis enthusiasts.

3Doja
CategoryRecreational Cannabis
Description

Premium, hand-crafted cannabis flower brand from British Columbia's Okanagan Valley with a West Coast, craft-style positioning.

4Deep Space
CategoryRecreational Cannabis
Description

High-potency cannabis beverage and edible brand offering cola and Limon Splashdown flavours, marketed to experienced consumers.

5Storz & Bickel Vaporizers
CategoryMedical Devices
Description

Premium medical-grade vaporizer devices including Volcano, Mighty, Crafty+, and Volcano Medic 2 models, sold for medical and consumer cannabis vaporization.

6Spectrum Therapeutics
CategoryMedical Cannabis
Description

International medical cannabis brand with color-coded classification system, offering medical cannabis products to patients and healthcare professionals in Canada, Germany, Australia, UK, Poland, and Czech Republic.

7Wana Edibles
CategoryRecreational Cannabis
Description

Cannabis gummies and edible products offering multiple cannabinoid ratios and terpene formulations.

8Ace Valley
CategoryRecreational Cannabis
Description

Cannabis brand offering ready-to-enjoy cannabis beverages for consumers.

9Twd.
CategoryRecreational Cannabis
Description

Simple, affordable Canadian cannabis brand offering high-quality products for everyday consumers.

10Hiway
CategoryRecreational Cannabis
Description

High-quality, high-value cannabis brand for experienced consumers, including PAX Era pods with cannabis-derived distillate and custom terpene blends.

11LivRelief
CategoryTopicals
Description

Infused transdermal creams with proprietary delivery system for CBD and THC, formulated with plant-based ingredients and terpenes.

12Canopy Medical
CategoryMedical Cannabis
Description

Pharmaceutical manufacturer producing, importing, and releasing medical cannabis products in Germany for patients and healthcare providers.

13Deelish
CategoryRecreational Cannabis
Description

Value-tier cannabis brand offering high-potency (26-33% THC) products at affordable prices, targeting everyday consumers in Ontario and Alberta.

14Claybourne
CategoryRecreational Cannabis
Description

Cannabis brand offering pre-rolls, concentrates, and premium liquid diamond vapes; Frosted Flyers line won 'Best Infused Pre-Roll' at 2026 Grow Up Awards.

15Apollo Cannabis Clinics
CategoryMedical Services
Description

Virtual medical cannabis consultation service connecting Canadian patients with healthcare practitioners to manage conditions such as chronic pain and anxiety.

16Vert
CategoryRecreational Cannabis
Description

Quebec-exclusive cannabis brand offering strains such as Green Cush and Sour Kush through SQDC retail channels.

Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2026-03-16
Description

Canopy Growth acquired MTL Cannabis for approximately $125 million CAD (equity value), creating Canada's leading medical cannabis business by revenue. MTL brings cultivation facilities, post-harvest assets, Canada House clinics, and online medical channel. The acquisition closed March 16, 2026, with $10 million in expected annualized synergies within 18 months. Key MTL executives joined Canopy's leadership team.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Partnership with Procaps for formulation and encapsulation of cannabis products in Latin America, establishing Colombia as the regional production hub. Procaps provides formulation and manufacturing capabilities for cannabis-derived products.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Canopy Growth holds an option to acquire Acreage Holdings upon federal permissibility of THC in the U.S. The arrangement provides Canopy with access to the U.S. cannabis market through Acreage's multi-state operations, with fixed consideration of approximately $300 million plus up to $700 million earnout.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Canopy Growth holds an option to acquire Wana Brands upon U.S. federal permissibility of THC. Wana is an award-winning cannabis gummy brand expanding Canopy's edible product capabilities.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight7 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Trulieve is a leading U.S. multi-state cannabis operator with strong retail density and branded consumer products. Comparable as a large branded cannabis operator; relevant given Canopy's U.S. optionality through Acreage.

TypeDirect peer
Description

Tilray is a Canadian-headquartered global cannabis company with diversified branded recreational and medical cannabis operations, plus beverage and wellness adjacencies. It is the closest direct competitor to Canopy in product breadth, international medical footprint, and multi-brand Canadian strategy following its merger with Aphria.

TypeDirect peer
Description

Aurora Cannabis is a Canadian licensed producer with global medical cannabis operations across Europe and a Canadian adult-use portfolio. Comparable to Canopy in cultivation scale, medical market focus, and history of significant restructuring and cost reduction efforts.

TypeDirect peer
Description

Cronos Group is a Canadian licensed cannabis producer with international operations and consumer brands including Spinach and Peace Naturals. Comparable to Canopy as a publicly traded Canadian LP with multi-brand portfolio and similar restructuring challenges.

TypeDirect peer
Description

OrganiGram is a Canadian cannabis producer focused on premium dried flower, pre-rolls, vapes, and edibles. Comparable to Canopy in serving Canadian adult-use markets with branded product portfolio and pursuing international expansion.

TypeBroad incumbent
Description

Curaleaf is one of the largest U.S. multi-state cannabis operators with a broad branded portfolio across flower, vapes, edibles, and topicals. Relevant as a large-scale MSO peer for Canopy's potential U.S. entry via Acreage, though its U.S.-only focus contrasts with Canopy's international medical footprint.

TypeBroad incumbent
Description

Jazz Pharmaceuticals acquired GW Pharmaceuticals, the maker of Epidiolex (cannabidiol), establishing a major pharmaceutical presence in cannabinoid-based therapeutics. Comparable to Canopy's medical cannabis and Canopy Medical pharmaceutical manufacturing ambitions in Germany.

TypeBroad incumbent
Description

Green Thumb is a U.S. multi-state cannabis operator with branded consumer products including vapes and edibles. Relevant as a U.S. peer for benchmarking the brand-driven consumer strategy Canopy could deploy if U.S. entry via Acreage materializes.

TypeDirect peer
Description

Aphria was a major Canadian cannabis producer with adult-use and medical portfolios and a strong Quebec presence. Highly relevant because Canopy's Chief Business Development Officer previously served as Aphria's CLO, and Aphria's Quebec and medical assets parallel Canopy's post-MTL positioning.

TypeEmerging player
Description

Demetrix develops fermented cannabinoid ingredients for pharmaceutical and consumer applications. Comparable as an emerging science-driven cannabis therapeutics player relevant to Canopy's medical and pharmaceutical-grade positioning, particularly in European markets.

Market position
Strengths1 record

Each record includes

Headline, Details, Source

Weaknesses1 record

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles7 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries8 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds18 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors10 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A20 records

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment5 records

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Canopy Growth

Cannabis Productscanopygrowth.com

Canopy Growth is a Canadian publicly traded cannabis company that manufactures and sells medical and recreational cannabis products, medical vaporizers, and cannabis-infused consumer goods across Canada, Germany, and other international markets through a portfolio of 15+ brands.

What Canopy Growth does

Canopy Growth Corporation is a Canadian publicly traded cannabis consumer products company (TSX: WEED, NASDAQ: CGC) headquartered in Smiths Falls, Ontario, with operations spanning medical cannabis cultivation, recreational cannabis branded products, medical vaporizer devices, and pharmaceutical manufacturing. Founded in 2003, the company operates a portfolio of more than 15 cannabis brands including Tweed (flagship consumer brand), 7Acres (premium flower), Doja (craft), Deep Space (high-potency beverages and gummies), Wana (edibles), Twd. and Deelish (value segments), and Spectrum Therapeutics (international medical). It also owns Storz & Bickel, a German manufacturer of medical-grade vaporizers including the Volcano Medic 2 with ISO 13485 certification, and Canopy Medical, a German pharmaceutical manufacturer for medical cannabis products. Distribution reaches Canada (provincial retailers plus company-owned Tweed and Tokyo Smoke stores), Germany (the largest European medical cannabis market), UK, Poland, Czech Republic, and Australia, with the company claiming product availability in over 50 countries.

The company generates revenue primarily through one-time product sales of dried cannabis flower, pre-rolls, vape cartridges, edibles, beverages, gummies, and softgels across Canadian recreational and medical markets plus international medical cannabis channels, supplemented by hardware sales of vaporizer devices and professional services revenue from Apollo Cannabis Clinics virtual consultations and Canada House clinics acquired through MTL Cannabis. Canopy operates over 10.5 million square feet of cultivation capacity including over 1 million square feet GMP-certified, and recently completed the acquisition of MTL Cannabis Corp. for approximately $125 million CAD in March 2026, which is expected to deliver $10 million in annualized synergies within 18 months. The company has undergone significant financial restructuring, moving from a net debt position of $172.6 million to a net cash position of $131.3 million through a January 2026 recapitalization that included a $150 million USD term loan and extension of all debt maturities to at least January 2031, with management targeting positive adjusted EBITDA by FY2027.

Constellation Brands holds approximately 38.6% of common shares as the largest shareholder following cumulative investments exceeding C$5 billion. FY2026 net revenue was $284.6 million (6% growth YoY), with notable momentum in Canadian medical cannabis (27% Q4 YoY growth) and international markets (68% Q4 YoY growth). The company is pursuing U.S. market entry through Canopy USA contingent on federal THC permissibility, leveraging its Acreage Holdings option arrangement, and faces a Management Cease Trade Order from the Ontario Securities Commission requiring restatement of FY2024 and FY2025 results due to non-cash warrant accounting issues.

Canopy Growth firmographics

Firmographics
Name
Canopy Growth
Legal name
Canopy Growth Corporation
Website
https://canopygrowth.com
Company type
Public
Founded year
2003
Operating status
Operating
Headcount range
501–1,000 employees
Short description
Canopy Growth is a Canadian publicly traded cannabis company that manufactures and sells medical and recreational cannabis products, medical vaporizers, and cannabis-infused consumer goods across Canada, Germany, and other international markets through a portfolio of 15+ brands.
Ownership category
akta.pro rank

Canopy Growth industry classification

Industry
Product category
Cannabis Products
NAICS
Tobacco Manufacturing (3122)
SIC
Medicinal Chemicals & Botanical Products (2833)
akta.pro primary industry
Cannabis Dispensary + Delivery/Online Pickup (Omnichannel Retail) (CRANAFAG)
akta.pro secondary industries
Cannabis Dispensary + Ancillary Retail (Accessories, CBD/Hemp, Merchandise) (CRANAFAH), Dispensary-Owned Online Ordering & Delivery (Direct-to-Consumer) (CRANAGAE), Cannabis Accessories & Smoke Shops (Pipes, Papers, Grinders) (CRANAHAG)

Keywords

  • Cannabis products
  • Medical cannabis
  • Cannabis cultivation
  • Vaporizer devices
  • Cannabis brands

Where Canopy Growth is headquartered

Location

Headquarters

HQ city
Smiths Falls
HQ country
Canada
HQ region
North America

Offices3 records

Markets served

Canopy Growth business model

Business model
GTM type
B2C
Offering type
Hardware or Manufacturing
Cost components
Personnel, Supply Chain, Operations, Marketing or Sales, Technology or R&D, Infrastructure

Revenue model

  1. Cannabis Product Sales: Revenue from selling dried cannabis flower, pre-rolls, vape cartridges, edibles, beverages, and gummies through Canadian recreational and medical markets, as well as international medical cannabis markets
  2. Medical Device Sales (Storz & Bickel): Revenue from manufacturing and selling vaporizer devices for medical and consumer use, including Volcano, Crafty, and Mighty product lines
  3. Cultivation Services: Revenue from medical cannabis cultivation and processing, including premium flower production through MTL Cannabis facilities serving Canadian and international markets
  4. Medical Cannabis Clinics: Revenue from Apollo Cannabis Clinics providing virtual medical cannabis consultations across Canada

Go-to-market motion2 records

Distribution channels4 records

Marketing channels5 records

Canopy Growth product offering

Product offering

Core offering

Canopy Growth is a diversified cannabis company that cultivates, manufactures, and sells cannabis products—including dried flower, pre-rolls, vape cartridges, edibles, beverages, and softgels—through a portfolio of 15+ brands across Canadian recreational, Canadian medical, and international medical cannabis markets. The company also produces medical-grade vaporizer devices through its Storz & Bickel subsidiary and operates virtual medical cannabis clinics through Apollo Cannabis Clinics and Canada House Clinics.

Product overview

Canopy Growth is a diversified cannabis company operating a multi-brand portfolio across recreational and medical cannabis segments. The product portfolio spans multiple categories including dried flower, pre-rolls, vape cartridges, beverages, gummies, softgels, and medical devices. Core Canadian consumer brands include Tweed (flagship), 7Acres (premium flower), Doja (craft), Deep Space (beverages), Wana (gummies), Hiway (value), and Twd. (affordable simple products). Medical cannabis is served through Spectrum Therapeutics internationally and Apollo Cannabis Clinics in Canada. The company also owns Storz & Bickel, a leading vaporizer manufacturer producing medical-grade devices including Volcano Medic 2. The recent acquisition of MTL Cannabis added premium flower cultivation capabilities and medical clinic operations (Canada House). Products range from budget/value offerings (Deelish, Twd.) to premium/specialty tiers (Doja, 7Acres, Claybourne), with the Storz & Bickel subsidiary providing medical device technology across multiple regulated markets.

Differentiator

Problem solved

Functional benefit

Brands

  • Apollo Cannabis Clinics: Virtual medical cannabis clinic offering consultations across Canada
  • Tokyo Smoke
  • Martha Stewart

Products and services

  • Tweed Flagship cannabis brand offering dried flower, pre-rolls, and other cannabis products to recreational and medical consumers globally.
  • 7Acres Premium cannabis brand producing high-end dried flower and pre-roll products for cannabis enthusiasts.
  • Doja Premium, hand-crafted cannabis flower brand from British Columbia's Okanagan Valley with a West Coast, craft-style positioning.
  • Deep Space High-potency cannabis beverage and edible brand offering cola and Limon Splashdown flavours, marketed to experienced consumers.
  • Storz & Bickel Vaporizers Premium medical-grade vaporizer devices including Volcano, Mighty, Crafty+, and Volcano Medic 2 models, sold for medical and consumer cannabis vaporization.
  • Spectrum Therapeutics International medical cannabis brand with color-coded classification system, offering medical cannabis products to patients and healthcare professionals in Canada, Germany, Australia, UK, Poland, and Czech Republic.
  • Wana Edibles Cannabis gummies and edible products offering multiple cannabinoid ratios and terpene formulations.
  • Ace Valley Cannabis brand offering ready-to-enjoy cannabis beverages for consumers.
  • Twd. Simple, affordable Canadian cannabis brand offering high-quality products for everyday consumers.
  • Hiway High-quality, high-value cannabis brand for experienced consumers, including PAX Era pods with cannabis-derived distillate and custom terpene blends.
  • LivRelief Infused transdermal creams with proprietary delivery system for CBD and THC, formulated with plant-based ingredients and terpenes.
  • Canopy Medical Pharmaceutical manufacturer producing, importing, and releasing medical cannabis products in Germany for patients and healthcare providers.
  • Deelish Value-tier cannabis brand offering high-potency (26-33% THC) products at affordable prices, targeting everyday consumers in Ontario and Alberta.
  • Claybourne Cannabis brand offering pre-rolls, concentrates, and premium liquid diamond vapes; Frosted Flyers line won 'Best Infused Pre-Roll' at 2026 Grow Up Awards.
  • Apollo Cannabis Clinics Virtual medical cannabis consultation service connecting Canadian patients with healthcare practitioners to manage conditions such as chronic pain and anxiety.
  • Vert Quebec-exclusive cannabis brand offering strains such as Green Cush and Sour Kush through SQDC retail channels.

Quantifiable outcome

  • 27% growth in Canadian medical cannabis net revenue in Q4 FY2026
  • +3 more outcomes

Companies that use Canopy Growth

Customer profile

Named customers2 records

Segments4 records

Ideal customer profiles3 records

Canopy Growth technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Canopy Growth partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered flagship, core and minor.

  • MTL Cannabis Corp.flagshipStrategic or Co-development Partner · 16 March 2026Canopy Growth acquired MTL Cannabis for approximately $125 million CAD (equity value), creating Canada's leading medical cannabis business by revenue. MTL brings cultivation facilities, post-harvest assets, Canada House clinics, and online medical channel. The acquisition closed March 16, 2026, with $10 million in expected annualized synergies within 18 months. Key MTL executives joined Canopy's leadership team.
  • ProcapscoreStrategic or Co-development PartnerPartnership with Procaps for formulation and encapsulation of cannabis products in Latin America, establishing Colombia as the regional production hub. Procaps provides formulation and manufacturing capabilities for cannabis-derived products.
  • Acreage HoldingscoreStrategic or Co-development PartnerCanopy Growth holds an option to acquire Acreage Holdings upon federal permissibility of THC in the U.S. The arrangement provides Canopy with access to the U.S. cannabis market through Acreage's multi-state operations, with fixed consideration of approximately $300 million plus up to $700 million earnout.
  • Wana BrandsminorStrategic or Co-development PartnerCanopy Growth holds an option to acquire Wana Brands upon U.S. federal permissibility of THC. Wana is an award-winning cannabis gummy brand expanding Canopy's edible product capabilities.

Scale indicators6 records

Recent moves7 records

Expansion highlights7 records

Canopy Growth competitors and assessment

Company assessment

Broad incumbents

  • Trulieve Cannabis: Trulieve is a leading U.S. multi-state cannabis operator with strong retail density and branded consumer products. Comparable as a large branded cannabis operator; relevant given Canopy's U.S. optionality through Acreage.
  • Curaleaf Holdings: Curaleaf is one of the largest U.S. multi-state cannabis operators with a broad branded portfolio across flower, vapes, edibles, and topicals. Relevant as a large-scale MSO peer for Canopy's potential U.S. entry via Acreage, though its U.S.-only focus contrasts with Canopy's international medical footprint.
  • Jazz Pharmaceuticals: Jazz Pharmaceuticals acquired GW Pharmaceuticals, the maker of Epidiolex (cannabidiol), establishing a major pharmaceutical presence in cannabinoid-based therapeutics. Comparable to Canopy's medical cannabis and Canopy Medical pharmaceutical manufacturing ambitions in Germany.
  • Green Thumb Industries: Green Thumb is a U.S. multi-state cannabis operator with branded consumer products including vapes and edibles. Relevant as a U.S. peer for benchmarking the brand-driven consumer strategy Canopy could deploy if U.S. entry via Acreage materializes.

Direct peers

  • Tilray Brands: Tilray is a Canadian-headquartered global cannabis company with diversified branded recreational and medical cannabis operations, plus beverage and wellness adjacencies. It is the closest direct competitor to Canopy in product breadth, international medical footprint, and multi-brand Canadian strategy following its merger with Aphria.
  • Aurora Cannabis: Aurora Cannabis is a Canadian licensed producer with global medical cannabis operations across Europe and a Canadian adult-use portfolio. Comparable to Canopy in cultivation scale, medical market focus, and history of significant restructuring and cost reduction efforts.
  • Cronos Group: Cronos Group is a Canadian licensed cannabis producer with international operations and consumer brands including Spinach and Peace Naturals. Comparable to Canopy as a publicly traded Canadian LP with multi-brand portfolio and similar restructuring challenges.
  • OrganiGram Holdings: OrganiGram is a Canadian cannabis producer focused on premium dried flower, pre-rolls, vapes, and edibles. Comparable to Canopy in serving Canadian adult-use markets with branded product portfolio and pursuing international expansion.
  • Aphria (legacy, now part of Tilray): Aphria was a major Canadian cannabis producer with adult-use and medical portfolios and a strong Quebec presence. Highly relevant because Canopy's Chief Business Development Officer previously served as Aphria's CLO, and Aphria's Quebec and medical assets parallel Canopy's post-MTL positioning.

Emerging players

  • Demetrix (Amyris subsidiary): Demetrix develops fermented cannabinoid ingredients for pharmaceutical and consumer applications. Comparable as an emerging science-driven cannabis therapeutics player relevant to Canopy's medical and pharmaceutical-grade positioning, particularly in European markets.

Market position

Strengths1 record

Weaknesses1 record

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Canopy Growth social profiles

Digital presence

Canopy Growth compliance and trust

Trust signal

Compliance1 record

Canopy Growth financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Canopy Growth leadership team

Management profile

Number of profiles

Profiles7 records

Canopy Growth subsidiaries and ownership

Company hierarchy

Subsidiaries8 records

Canopy Growth funding detail

Funding detail

Funding overview

Funding rounds18 records

Investors10 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Canopy Growth M&A and investment

M&A and investment

M&A20 records

Investments5 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Canopy Growth

What does Canopy Growth do?

Canopy Growth is a diversified cannabis company that cultivates, manufactures, and sells cannabis products—including dried flower, pre-rolls, vape cartridges, edibles, beverages, and softgels—through a portfolio of 15+ brands across Canadian recreational, Canadian medical, and international medical cannabis markets. The company also produces medical-grade vaporizer devices through its Storz & Bickel subsidiary and operates virtual medical cannabis clinics through Apollo Cannabis Clinics and Canada House Clinics.

Is Canopy Growth a public or private company?

Canopy Growth is a public company. It is classified as public and is currently operating.

When was Canopy Growth founded?

Canopy Growth was founded in 2003. It employs 501 to 1,000 people.

Where is Canopy Growth based?

Canopy Growth is headquartered in Smiths Falls, Canada, in the North America region.

How does Canopy Growth make money?

Four revenue lines are on record. Cannabis Product Sales are the primary driver. The others are medical Device Sales (Storz & Bickel), cultivation Services and medical Cannabis Clinics.

Who are Canopy Growth's main competitors?

Broad incumbents on record are Trulieve Cannabis, Curaleaf Holdings, Jazz Pharmaceuticals and Green Thumb Industries. Direct peers are Tilray Brands, Aurora Cannabis, Cronos Group, OrganiGram Holdings and Aphria (legacy, now part of Tilray). Demetrix (Amyris subsidiary) is listed as an emerging player.

Does Canopy Growth have an API?

No public API is recorded for Canopy Growth.

What industry is Canopy Growth in?

Canopy Growth's product category is Cannabis Products. Its primary akta.pro industry code is CRANAFAG, Cannabis Dispensary + Delivery/Online Pickup (Omnichannel Retail), with a secondary code of CRANAFAH, Cannabis Dispensary + Ancillary Retail (Accessories, CBD/Hemp, Merchandise). Its NAICS code is 3122 and its SIC code is 2833.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
The Motley FoolCan Canopy Growth Survive Another 5 Years?Canopy Growth burned CA$25 million in operating cash flow in its most recent quarter, up from CA$10 million a year earlier. With CA$336.6 million in cash and cash equivalents, the company is not in imminent danger of running out of cash, but its stock has lost 99% of its value in five years.The Motley FoolCan Canopy Growth Survive Another 5 Years?Canopy Growth burned CA$25 million in operating cash flow in its most recent quarter, up from CA$10 million a year earlier. With CA$336.6 million in cash and cash equivalents, the company is not in imminent danger of running out of cash, but its stock has lost 99% of its value in five years.American Banking and Market NewsCanopy Growth Corporation (NASDAQ:CGC) Receives Consensus Rating of “Hold” from AnalystsCanopy Growth received a consensus "Hold" rating from five analysts, with one sell, two holds, and two buys. The stock opened at $0.90, down 3.1%, after Q2 EPS of -$0.02 beat estimates of -$0.04. Analysts expect -$0.1 EPS for the current year.The Motley FoolCanopy Growth Is Closing in on Positive EBITDA. Should You Buy the Stock?Canopy Growth reported Q1 fiscal 2027 net revenue of $57.4 million, up 13% year over year, with adjusted EBITDA loss narrowing to $2.3 million from $5.7 million. The company expects positive adjusted EBITDA in fiscal 2027, aided by MTL Cannabis integration and cost savings. Free cash flow worsened, but cash balance remains at $241.4 million.The Motley FoolCanopy Growth Is Closing in on Positive EBITDA. Should You Buy the Stock?Canopy Growth reported Q1 fiscal 2027 net revenue of $57.4 million, up 13% year over year, with adjusted EBITDA loss narrowing to $2.3 million from $5.7 million. The company expects positive adjusted EBITDA in fiscal 2027, aided by MTL Cannabis integration and cost savings. Free cash flow worsened, but cash balance remains at $241.4 million.YahooCanopy Growth Appoints Sebastian Blöte as Country Manager for GermanyCanopy Growth appointed Sebastian Blöte as Country Manager for Germany, effective October 1, 2026. He will lead commercial strategy, sales expansion, and partnerships in the German medical cannabis market. The appointment follows recent growth and supply capability improvements.Investing.comStock Market News - Investing.com IndiaCanopy Growth Corporation adjourned its annual general and special meeting after failing to achieve quorum. The meeting will reconvene on October 23, 2026, at 1:00 p.m. ET, with shareholders having until 9:00 a.m. ET to submit votes. The company will continue soliciting votes on the proposals.Investing.comLatest Company News - Investing.comCanopy Growth Corporation adjourned its annual general and special meeting on Friday after failing to achieve quorum. The meeting will reconvene on October 23, 2026, at 1:00 p.m. ET via live audio webcast, with shareholders having until 9:00 a.m. ET to submit votes.YahooCanopy Growth Is Eyeing Another Reverse Stock Split. Will It Be Enough to Light a Fire Beneath the Beaten-Down Pot Stock?Canopy Growth is seeking shareholder approval for another reverse stock split, with the vote set for Sept. 25. Shares have fallen roughly 80% from pre-split levels and are now below $1, prompting the move. The company reported a 13% top-line sales increase in fiscal 2027 Q1, though it still lost money.The Motley FoolCanopy Growth Is Eyeing Another Reverse Stock Split. Will It Be Enough to Light a Fire Beneath the Beaten-Down Pot Stock?Canopy Growth is seeking shareholder approval for another reverse stock split after its shares fell below $1. The vote is set for Sept. 25, and the company expects to see performance improve. Shareholders likely have little choice but to approve.